普仑司特
|
|
- CAS号:
- 150821-03-7
- 英文名:
- 8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran
- 英文别名:
- PRANLUKASTHEMIHYDRATE;Pranlukast hemihydrate >=98% (HPLC), white solid;N-[4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phe...;8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran;N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide,hydrate;N-[4-oxo-2-(1H-1,2,3,4-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide hydrate;N-[4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-benzamide hemihydrate;Benzamide,N-[4-oxo-2-(2H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-,hydrate (2:1);Pranlukast hydrateQ: What is
Pranlukast hydrate Q: What is the CAS Number of
Pranlukast hydrate Q: What is the storage condition of
Pranlukast hydrate
- 中文名:
- 普仑司特
- 中文别名:
- 半水普仑司特;普仑司特水合物;普鲁司特 水合物;普鲁司特半水合物;普伦司特半水合物;化合物 PRANLUKAST HEMIHYDRATE
- CBNumber:
- CB22130178
- 分子式:
- C27H25N5O5
- 分子量:
- 499.53
- MOL File:
- 150821-03-7.mol
|
|
|
普仑司特化学性质
-
储存条件:
-
-20°C
-
|
-
溶解度:
-
DMSO: ≥10mg/mL
-
|
-
形态:
-
white solid
-
|
普仑司特性质、用途与生产工艺
Pranlukast hemihydrate (ONO-1078 hemihydrate) 是一种高效的竞争性的选择性 leukotriene 拮抗剂。Pranlukast 抑制 [3H]LTE4,[3H]LTD4 和 [3H]LTC4 与肺膜结合,Ki 分别为 0.63±0.11,0.99±0.19 和 5640±680 nM。
LTE
4
0.63 nM (Ki)
|
LTD
4
0.99 nM (Ki)
|
LTC
4
5640 nM (Ki)
|
In the radioligand binding assay, Pranlukast (ONO-1078) inhibits [
3
H]LTE
4
, [
3
H]LTD
4
, and [
3
H]LTC
4
bindings to lung membranes with K
i
s of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively. The antagonism of Pranlukast against [
3
H]LTD
4
binding is competitive. In functional experiments, Pranlukast shows competitive antagonism against the LTC
4
- and LTD
4
-induced contractions of guinea pig trachea and lung parenchymal strips with a pA
2
range of 7.70 to 10.71. In the presence of an inhibitor of the bioconversion of LTC
4
to LTD
4
, Pranlukast also antagonizes the LTC
4
-induced contraction of guinea pig trachea (pA
2
=7.78). Pranlukast significantly reverses the LTD
4
-induced prolonged contraction without effect on the KCl- and BaCl
2
-induced contractions of guinea pig trachea. Oxygen-glucose deprivation (OGD)-induced nuclear translocation of CysLT
1
receptors is inhibited by pretreatment with the CysLT
1
receptor antagonist Pranlukast (10 μM). Pranlukast protects endothelial cells against ischemia-like injury. The effects of the CysLT
1
receptor antagonist Pranlukast and the 5-lipoxygenase inhibitor Zileuton on translocation are also assessed. The results show that Pranlukast, but not Zileuton, inhibits the translocation of the CysLT
1
receptor 6 h after OGD.
Carrageenan (CAR, 5 mg per mouse) is injected i.p. 24 h before LPS (50 p,g per mouse) is injected i.v. Various doses of Pranlukast (ONO-1078; 40, 20, and 10 mmol/kg), AA-861 (20, 10, and 5 mmol/kg), Indomethacin (40 mmollkg), and the controls are injected s.c. into mice 30 min before they are challenged with 50 p,g of LPS. The maximum soluble doses are 0.6 mmol/mL in 10% DMSO for AA-861 and 1.2 mmol/mL in 10% ethanol for Pranlukast. These solutions are used as the maximum doses for the treatments. The mortality of mice is significantly decreased in AA-861- Pranlukast-treated mice relative to that in the control mice. Pretreatment with CAR (5 mg i.p.) renders the mice more sensitive to the effect of LPS. Although the survival rate of mice treated with each solvent is 20% at 72 h after LPS (50 p,g per mouse) administration, s.c. treatment with AA-861 (20 mmol/kg) or Pranlukast (40 mmol/kg) significantly increases the survival rate after the LPS administration (AA-861, P<0.001; Pranlukast, P<0.01).
普仑司特
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/01/25 | HY-B0290A | 普仑司特 Pranlukast hemihydrate | 150821-03-7 | 50mg | 600元 |
2024/01/25 | HY-B0290A | 普仑司特 Pranlukast hemihydrate | 150821-03-7 | 10mM * 1mLin DMSO | 660元 |
普仑司特
生产厂家
全球有 94家供应商
普仑司特国内生产厂家
150821-03-7, 普仑司特 相关搜索:
- 合成
- C54H48N10O9
- 2C27H23N5O4H2O
- 普伦司特半水合物
- 化合物 PRANLUKAST HEMIHYDRATE
- 普鲁司特 水合物
- 普鲁司特半水合物
- 普仑司特水合物
- 半水普仑司特
- 150821-03-7
- N-[4-oxo-2-(1H-1,2,3,4-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide hydrate
- N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide,hydrate
- Pranlukast hydrateQ: What is
Pranlukast hydrate Q: What is the CAS Number of
Pranlukast hydrate Q: What is the storage condition of
Pranlukast hydrate
- N-[4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phe...
- Benzamide,N-[4-oxo-2-(2H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-,hydrate (2:1)
- Pranlukast hemihydrate >=98% (HPLC), white solid
- N-[4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-benzamide hemihydrate
- 8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran
- PRANLUKASTHEMIHYDRATE